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Early-onset autoimmune vitiligo associated with an
enhancer variant haplotype that upregulates class II
HLA expression
Ying Jin1,2, Genevieve H.L. Roberts1, Tracey M. Ferrara1, Songtao Ben1, Nanja van Geel3, Albert Wolkerstorfer4,
Khaled Ezzedine5, Janet Siebert6, Charles P. Neff7, Brent E. Palmer7, Stephanie A. Santorico1,8 &
Richard A. Spritz1,2
Vitiligo is an autoimmune disease in which melanocyte destruction causes skin depigmen-
tation, with 49 loci known from previous GWAS. Aiming to deﬁne vitiligo subtypes,
we discovered that age-of-onset is bimodal; one-third of cases have early onset (mean
10.3 years) and two-thirds later onset (mean 34.0 years). In the early-onset subgroup we
found novel association with MHC class II region indel rs145954018, and independent
association with the principal MHC class II locus from previous GWAS, represented
by rs9271597; greatest association was with rs145954018del-rs9271597A haplotype
(P= 2.40 × 10−86, OR= 8.10). Both rs145954018 and rs9271597 are located within
lymphoid-speciﬁc enhancers, and the rs145954018del-rs9271597A haplotype is speciﬁcally
associated with increased expression of HLA-DQB1 mRNA and HLA-DQ protein by mono-
cytes and dendritic cells. Thus, for vitiligo, MHC regulatory variation confers extreme risk,
more important than HLA coding variation. MHC regulatory variation may represent a
signiﬁcant component of genetic risk for other autoimmune diseases.
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V itiligo is an autoimmune disease in which destruction ofskin melanocytes results in patches of white skin andhair1. In three previous genome-wide association studies
(GWAS), we identiﬁed 49 genetic loci associated with vitiligo
susceptibility2–6, most of which harbor genes involved in reg-
ulation of immune cells, apoptosis, and melanocyte function.
These ﬁt together in a general model of melanocyte autoimmune
pathogenesis7.
Vitiligo is frequently associated with other autoimmune dis-
eases, particularly autoimmune thyroid disease, type 1 diabetes,
pernicious anemia, rheumatoid arthritis, systemic lupus erythe-
matosus, and Addison disease8, and a number of vitiligo sus-
ceptibility loci are shared with these other diseases7. Chief among
these is the Major Histocompatibility Complex (MHC), with
vitiligo having independent genetic associations in both the MHC
class I and class II regions2,4,5. However, unlike for many other
autoimmune diseases, for vitiligo principal MHC associations
localize to intergenic non-coding regions9,10, rather than coding
variants that alter HLA protein structure and thereby affect
binding and presentation of peptide antigens.
In the present study, we investigate clinical variation among
vitiligo cases in an attempt to deﬁne vitiligo subgroups and to
then explore differential underlying genetic basis. We began by
characterizing secondary vitiligo phenotypes, starting with age-of-
onset and association with other autoimmune diseases. Unex-
pectedly, we ﬁnd that vitiligo age-of-onset is bimodal, consisting
of early-onset and late-onset subgroups. To investigate genetic
differences between these two subgroups, we then categorized
vitiligo cases as early-onset or late-onset and carried out stratiﬁed
GWAS of each subgroup separately. Speciﬁcally in the early-onset
subgroup, we identify a novel, very strong association with
rs145954018, an insertion-deletion (indel) polymorphism in the
MHC class II region. In both the early- and late-onset subgroups
we also observe independent association with a separate MHC
class II locus found by our previous vitiligo GWAS, represented
by rs9271597. Extreme vitiligo risk and early disease onset are
associated with the rs145954018del-rs9271597A haplotype that
includes the risk alleles of both variants; coding variation within
the classical HLA alleles on this haplotype does not independently
contribute to vitiligo risk. Surprisingly, we also observe lower
frequency of other, concomitant autoimmune diseases in early-
onset vitiligo cases than in late-onset cases. This may be explained
by the protective effects on these autoimmune diseases of HLA-
DRB1*13:01, which typically occurs on the background of the
early-onset rs145954018del-rs9271597A haplotype.
Both rs145954018 and rs9271597 are located within different
lymphoid-speciﬁc enhancers predicted by ENCODE11. Accord-
ingly, we examined the effect of each variant on expression of
neighboring HLA genes. We ﬁnd that rs145954018del and the
early-onset rs145954018del-rs9271597A haplotype are speciﬁcally
associated with signiﬁcantly elevated expression of HLA-DQ
mRNA and protein by professional antigen presenting cells
including peripheral blood monocytes and dendritic cells. Thus,
for vitiligo, extreme genetic risk and early disease onset are
genetically associated with a MHC class II haplotype that is
associated with increased HLA-DQ expression, rather than with
speciﬁc HLA alleles that produce structurally different HLA
proteins.
Results
Vitiligo consists of early-onset and late-onset subgroups.
Among the total 4523 vitiligo cases of European ancestry in our
three previous GWAS and replication cohorts, the overall mean
age-of-onset was 25.9 years, SD 16.6 (Fig. 1), with no signiﬁcant
difference between males and females; males mean 26.5 years,
SD 16.8 and females mean 25.6 years, SD 16.5 (Supplementary
Figure 1), and the mean age-of-onset was similar in each of the
four constituent vitiligo case cohorts (GWAS1, mean 24.0 years,
SD 16.4; GWAS2, mean 27.5 years, SD 16.9; GWAS3, mean
27.3 years, SD 16.4; replication cohort, mean 26.3 years, SD 16.7).
However, in all four case cohorts the age-of-onset distribution
appeared non-normal, in both males and females (Supplementary
Figure 2). Statistical goodness of ﬁt analysis supported a bimodal
age-of-onset distribution composed of two overlapping normally
distributed subgroups (Fig. 1, Supplementary Table 1, and
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Fig. 1 Vitiligo age-of-onset is bimodal. The distribution of vitiligo age-of-onset and resultant ﬁnite mixture model is shown for the total 4523 cases from our
three previous vitiligo GWAS and replication study2,4,5. The blue line shows the full distribution, the red line the early-onset distribution (mean 10.3,
SD 5.6 years; 38.4%), and the green line the late-onset distribution (mean 34.0, SD 14.5 years; 61.6%). The overall and sex-speciﬁc distributions, resultant
ﬁnite mixture models, and overall and sex-speciﬁc mean ages-of-onset were very similar among the four constituent case cohorts. See also Supplementary
Figures 1, 2, and 3. Source data are provided as a Source Data ﬁle
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-08337-4
2 NATURE COMMUNICATIONS |          (2019) 10:391 | https://doi.org/10.1038/s41467-019-08337-4 | www.nature.com/naturecommunications
Supplementary Figure 3): an early-onset subgroup (mean
10.3 years, SD 5.6; 38.4%) and a late-onset subgroup (mean 34.0
years, SD 14.5; 61.6%), with similar proportions of early-onset
and late-onset cases in the four constituent case cohorts
(37.5:62.5%; 37.2:62.8%; 41.4:58.6%; 37.6:62.4%; Supplementary
Figure 3).
Early-onset vitiligo associated with MHC indel rs145954018.
To explore differential genetic underpinnings of early-onset vs.
late-onset vitiligo, we assigned cases from each GWAS cohort
to these subgroups, including only cases that could be classiﬁed
with >80% probability of belonging to one or the other subgroup.
Cases were then genetically matched with controls from the
corresponding GWAS12. After subgroup assignment and control
matching, the combined early-onset subgroup contained 704
cases and 9,031 controls and the combined late-onset subgroup
contained 1,467 cases and 19,156 controls. We then carried
out separate GWAS for each subgroup and tested effect size
differences for variants that showed genome-wide signiﬁcant
association (PCMH < 5.0 × 10−8) with vitiligo in either or both
subgroups.
A total 5,493 MHC and 771 non-MHC variants showed genome-
wide signiﬁcant association in one or both age-of-onset subgroups
(Supplementary Data File 1). As shown in Table 1 and Fig. 2, in the
early-onset subgroup greatest association was with two-base indel
variant (TG/del) rs145954018 (Plogistic= 3.47 × 10−54, OR= 4.62,
95% CI 3.81–5.61), located in the MHC class II region; rs145954018
did not achieve genome-wide signiﬁcance in the late-onset
subgroup (Plogistic= 4.50 × 10−5, OR= 1.47, 95% CI 1.22–1.75).
In the late-onset subgroup, greatest association was with the overall
most signiﬁcant variant in our previous vitiligo GWAS5, MHC class
II SNP (T/A) rs9271597 (Plogistic= 3.51 × 10−34, OR= 1.63, 95%
CI 1.51–1.77), which also showed strong association in the early-
onset case subgroup (Plogistic= 2.31 × 10−40, OR= 2.23, 95% CI
1.98–2.51) (Table 1 and Fig. 2). Thus, rs145954018 is speciﬁcally
associated with early-onset vitiligo whereas rs9271597 is generically
associated with vitiligo risk.
Stepwise logistic regression analysis indicated that rs145954018
was the only variant representing the early-onset association
signal, whereas rs9271597 as well as rs9271600 and rs9271601, all
represent the generic association signal; these three SNPs are
located only 45 bases apart and are perfectly correlated (r2= 1.0)
in the European-ancestry population9. No other variants in the
MHC showed signiﬁcantly different effect sizes in the early-
versus late-onset vitiligo subgroups when the effects of
rs145954018 and rs9271597 were accounted for in stepwise
logistic regression analysis (Supplementary Data File 2). Addi-
tionally, no variants elsewhere in the genome (Supplementary
Data File 2), including the 49 other previous vitiligo susceptibility
loci (Supplementary Table 2), showed signiﬁcantly different effect
sizes comparing the early- and late-onset vitiligo subgroups.
As a replication test, we stratiﬁed our previous GWAS replication
case cohort into early-onset and late-onset subgroups as above,
randomly assigned controls to each subgroup, and genotyped
rs145954018 and rs9271597. As shown in Table 1,
rs145954018 showed far greater association and stronger effect
in the early-onset replication subgroup (Plogistic= 1.57 × 10−30,
OR= 5.48 95% CI 4.10–7.32) than in the late-onset replication
subgroup (Plogistic= 0.002, OR= 1.67, 95% CI 1.21–2.31). SNP
rs9271597 again was associated in both the early-onset subgroup
(Plogistic= 5.54 × 10−23, OR= 2.40, 95% CI: 2.02–2.85) and the
late-onset subgroup (Plogistic= 2.28 × 10−10, OR= 1.57, 95% CI:
1.37–1.81). These results conﬁrm that rs145954018 is speciﬁcally
associated with early-onset vitiligo, while rs9271597 is associated
in both subgroups.
Early vitiligo onset and rs145954018del-rs9271597A haplotype.
rs145954018 and rs9271597 are in almost complete LD
(D’= 0.98, r2= 0.04). The relatively uncommon rs145954018del
risk allele (MAF= 3.5% in our GWAS controls) almost always
occurs on the background of the relatively common risk allele of
generic SNP rs9271597 (MAF= 42.7%), together constituting a
haplotype that carries the risk alleles of both variants,
rs145954018del-rs9271597A. To determine whether rs145954018
and rs9271597 are independently associated with vitiligo sus-
ceptibility, we carried out multiple logistic regression analysis
including both variants in the same model (Supplementary
Table 3). Adjusting for rs9271597, rs145954018 was signiﬁcantly
associated with vitiligo in the early-onset subgroup (Pconditional=
1.01 × 10−31, OR= 3.35, 95% CI: 2.74–4.10), with a signiﬁcantly
(PZ= 2.27 × 10−14) higher OR than in the late-onset subgroup
(Pconditional= 0.16, OR= 1.15, 95% CI: 0.95–1.38). Adjusting for
rs145954018, the generic SNP, rs9271597, was signiﬁcantly
associated with vitiligo in both the early-onset (Pconditional=
2.99 × 10−24, OR= 1.91, 95% CI 1.68–2.16) and late-onset
(Pconditional= 2.04 × 10−31, OR= 1.62, 95% CI: 1.49–1.75) sub-
groups, with a marginally (PZ= 0.03) higher OR in the early-
onset subgroup. The replication study data yielded similar results
(Supplementary Table 3). These results show that both
rs145954018 and rs9271597 are independently associated with
vitiligo in the early-onset case subgroup.
To visualize the relationship between the rs145954018del-
rs9271597A haplotype and vitiligo age-of-onset, we plotted
haplotype frequency versus vitiligo age-of-onset. As shown
in Fig. 3, the frequency of the rs145954018del-rs9271597A
haplotype was strikingly non-linear, exhibiting dramatic elevation
in vitiligo cases with age-of-onset from about 5 to 9 years
Table 1 Principal MHC class II variants in the early- and late-onset subgroups
Early-onset Late-onset Effect size differencea
Variant Chr 6 Position
(Build 37)
EA/OA P value OR SE P value OR SE Z score P value
Combined GWASa
rs145954018 32440321 D/I 3.47 × 10−54 4.62 0.10 4.50 × 10−5 1.47 0.09 8.42 3.75 × 10−17
rs9271597 32591291 A/T 2.31 × 10−40 2.23 0.06 3.51 × 10−34 1.63 0.04 4.31 1.64 × 10−5
Replication studyb
rs145954018 32440321 D/I 1.57 × 10−30 5.48 0.15 0.002 1.67 0.17 5.32 1.04 × 10−7
rs9271597 32591291 A/T 5.54 × 10−23 2.40 0.09 2.28 × 10−10 1.57 0.07 3.70 2.16 × 10−4
Chr chromosome, EA effect allele, OA other allele, SE standard error of the logarithm of the OR
aObtained by logistic regression analysis including signiﬁcant eigenvectors from each GWAS as covariates
bObtained by logistic regression analysis
cA Z test32 was used to test effect size difference, with Z calculated as the difference between the logarithms of the ORs, divided by the square root of the sum of the variances of the logarithms of the
ORs, where Z follows a normal distribution
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(OR= 11.01, 95% CI: 8.75–13.87, Plogistic= 4.49 × 10−92), with
frequency of 18.5% in this group of cases versus about 3.5% in
controls. These results show that the rs145954018del-rs9271597A
haplotype is associated with remarkably high risk in children with
vitiligo onset at ages 5–9 years. Surprisingly, the mean age of
vitiligo onset was very similar in vitiligo cases carrying one (mean
19.8 years, SD 18.9) vs. two (mean 20.8 years, SD 15.1) copies of
the high-risk rs145954018del-rs9271597A haplotype, compared
to cases carrying only the reference rs145954018TG-rs9271597T
haplotype (mean 29.3 years, SD 16.8). This suggested that the
rs145954018del-rs9271597A haplotype might exert a dominant
effect, accelerating vitiligo age-of-onset by approximately nine
years. Comparison of additive and dominant logistic regression
models indicated that the rs145954018del-rs9271597A haplotype
indeed acts as a complete dominant, dramatically increasing
vitiligo risk, with estimated OR 8.10 (P= 2.40 × 10−86) (Supple-
mentary Table 4).
Early vitiligo onset not driven by HLA coding variation.
Imputation of MHC class II classical HLA alleles13 in our GWAS
data, analysis of classical HLA allele sequences in 20 genotyped
vitiligo cases (Supplementary Table 5), and alignment with
European-American MHC class II haplotype reference stan-
dards14 showed that the rs145954018del risk allele resides on
an extended MHC class II haplotype, rs145954018del–HLA-
DRB1*13:01–HLA-DRB3*01:01–rs9271597A–HLA-DQA1*01:03–
HLA-DQB1*06:03. To dissect the relative contributions of
rs149554018, rs9271597, and the classical HLA alleles to
vitiligo risk, we compared logistic regression models with
haplotypes deﬁned by different combinations of rs145954018,
HLA-DRB1*13:01, rs9271597, HLA-DQA1*01:03, and HLA-
DQB1*06:03. The best ﬁt model included only rs145954018 and
rs9271597 (Plogistic= 3.85 × 10−83); inclusion of any of the clas-
sical HLA alleles failed to improve the model (Supplementary
Table 6). Together, these ﬁndings indicate that extreme vitiligo
risk and early onset is principally associated with the
rs14595401del-rs9271597A haplotype; the classical HLA alleles
on the extended high-risk haplotype do not appear to show
additional independent effects on vitiligo risk.
rs145954018, rs9271597, and vitiligo heritability. Both
rs145954018 and rs9271597 showed larger effects in the early-onset
subgroup than the late-onset subgroup, so we compared their con-
tributions to vitiligo heritability (the fraction of risk attributable to
additive genetic variation; h2) in the two subgroups. In the early-
onset subgroup, total vitiligo h2= 0.55, of which rs145954018
accounts for 7.5%, rs9271597 accounts for 6.8%, and the two toge-
ther 11.4% of the total. In the late-onset subgroup, total vitiligo h2=
0.40, of which rs145954018 only accounts for 0.4%, rs9271597 for
3.6%, and the two together 3.7%. The other 49 vitiligo susceptibility
loci identiﬁed by GWAS altogether account for very similar fractions
of vitiligo h2 in the early-onset (13.3%) and late-onset (15.0%)
subgroups. The fraction of vitiligo h2 explained by rs145954018 is
nearly 20-fold higher in the early-onset subgroup than in the late-
onset subgroup, hence explaining a large proportion of the difference
in heritability between the early- and late-onset subgroups.
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Fig. 2 MHC class II associations in early- and late-onset vitiligo subgroups. –log10 PCMH values are shown for variants tested across the HLA-DRA through
HLA-DQB1 segment of the MHC class II region in the separate (a) early-onset and (b) late-onset case-control cohorts from the combined GWAS. Red
indicates higher r2 with rs145954018, blue indicates higher r2 with rs9271597, and white indicates low correlation with either rs145954018 or rs9271597.
Arrows show rs145954018 and rs9271597. Genes and nucleotide positions are from GRCh37/hg19. Note that –log10 PCMH value scales differ for early-
onset and late-onset subgroups. Source data are provided as a Source Data ﬁle
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rs145954018 increases HLA-DQB1 mRNA and HLA-DQ pro-
tein. The rs145954018 indel is located within an immune-speciﬁc
transcriptional enhancer (ENSEMBL Human Regulatory Feature
ENSR00000195683), between HLA-DRA and HLA-DQA1
(Fig. 4). Likewise, rs9271597 is located within another immune-
speciﬁc enhancer (ENSEMBL Human Regulatory Feature
ENSR00000195696), between HLA-DRB1 and HLA-DQA1, which
we previously found is associated with surface expression of
HLA-DQ and HLA-DR proteins on peripheral blood monocytes9.
We therefore hypothesized that rs145954018 and rs9271597
might both affect expression of HLA class II proteins, either
independently or synergistically. To test this, we assayed surface
expression of HLA-DQ and HLA-DR proteins on sorted per-
ipheral blood monocytes, dendritic cells, and B cells from 46
healthy subjects selected on the basis of rs145954018 and
rs9271597 genotypes and inferred haplotypes. As shown in Fig. 5,
the rs14595401del-rs9271596A haplotype and rs145954018del
allele (for which the results were identical because of LD) were
both associated with increased expression of HLA-DQ protein
on monocytes (Plinear= 4.84 × 10−4; Fig. 5a) and dendritic cells
(Plinear= 0.005; Fig. 5b), but were not associated with expression
of HLA-DR protein in either cell type (Plinear= 0.96 and Plinear=
0.81, respectively). Stepwise regression analysis showed that, after
adjusting for rs145954018, rs9271597A was marginally associated
with increased expression of HLA-DR (Pconditional= 0.04) on
monocytes, but was not associated with increased expression of
HLA-DQ on any of the cell types studied.
To assess whether the rs145954018del-rs9271597A haplotype
speciﬁcally affects expression of the HLA class II genes on the
same haplotype (in cis), we carried out allele-speciﬁc RNA-seq
analysis of peripheral blood RNA from three healthy subjects
from the protein study. Subject 1 carried two low-risk
rs145954018TG-rs9271597T haplotypes, while subjects 2 and 3
each carried one low-risk haplotype and one high-risk
rs145954018del-rs9271597A haplotype. As shown in Table 2,
subject 1 expressed similar amounts of HLA-DRB1, HLA-DQA1,
and HLA-DQB1 mRNA from each chromosome. However, the
two subjects heterozygous for the high-risk rs145954018del-
rs9271597A haplotype expressed about 2.6- and 2.1-fold more
total HLA-DQB1 mRNA, respectively. Furthermore, both subjects
expressed proportionately more transcripts from the HLA-
DQB1*06:03 allele in cis on the high-risk rs145954018del-
rs9271597A haplotype, than from the HLA-DQB1 allele on the
low-risk haplotype. These results indicate that the high-risk
rs145954018del-rs9271597A haplotype is speciﬁcally associated
with increased expression of the HLA-DQB1*06:03 allele on the
extended haplotype.
Early vitiligo onset and risk of other autoimmune diseases.
Vitiligo is epidemiologically associated with increased risk of
autoimmune thyroid disease, type 1 diabetes, pernicious anemia,
rheumatoid arthritis, systemic lupus erythematosus, and Addi-
son’s disease8,15. We considered that greater genetic risk for
vitiligo in the early-onset subgroup might result in greater fre-
quency of concomitant occurrence of these other autoimmune
diseases in early-onset cases than in late-onset cases. Surprisingly,
we observed the opposite: the frequency of other vitiligo-
associated autoimmune diseases was signiﬁcantly lower (PFisher
= 4.05 × 10−4) in early-onset cases (17.0%) than in late-onset
cases (22.4%, Supplementary Table 7).
The extended rs145954018del-rs9271597A haplotype is in
almost complete LD with HLA-DRB1*13:01 (D’= 0.98, r2=
0.53). HLA-DRB1*13:01 is associated with relative protection
from systemic lupus erythematosus, rheumatoid arthritis16, and
type 1 diabetes17 in European-derived populations. Thus, while
rs145954018del is associated with extreme vitiligo risk and early
disease onset, HLA-DRB1*13:01 might simultaneously confer
relative protection from other autoimmune diseases, and thus
might account for the reduced frequency of concomitant
autoimmunity in early-onset vitiligo cases. To test this, we
analyzed association between non-vitiligo autoimmunity and
HLA-DRB1*13:01 and rs145954018. Individually, both HLA-
DRB1*13:01 (Plogistic= 0.004, OR= 0.71, 95% CI 0.56-0.90) and
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Fig. 3 rs1459540del-rs9271597A haplotype frequency across vitiligo age-of-onset. Frequency of the rs145954018del-rs9271597A high-risk haplotype in
4,254 vitiligo cases is shown in 1-year age-of-onset intervals. Circles indicate means and bars 95% conﬁdence intervals, calculated using the binom.test
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rs145954018del (Plogistic= 0.04, OR= 0.74, 95% CI: 0.55–0.98)
showed signiﬁcant protective association against non-vitiligo
autoimmune diseases. However, after adjusting for the effect of
rs145954018, HLA-DRB1*13:01 was marginally protective against
non-vitiligo autoimmunity (Pconditional= 0.05, OR= 0.69, 95%
CI: 0.48–1.00), whereas adjusting for the effect of HLA-
DRB1*13:01, rs145954018del showed no association (P= 0.88,
OR= 1.04, 95% CI: 0.66–1.63) with non-vitiligo autoimmunity.
These results suggest that reduced occurrence of concomitant
autoimmunity in early-onset vitiligo cases is primarily associated
with the HLA-DRB1*13:01 allele rather than with rs145954018del.
Discussion
We have found that autoimmune vitiligo consists of two clinical
subgroups: early-onset (mean onset 10.3 years) and late-onset
(mean 34.0 years). At least two other autoimmune diseases that
are epidemiologically associated with vitiligo8,15, type 1 diabetes
and rheumatoid arthritis, likewise have early-onset and late-onset
forms18,19. For all three of these diseases, the magnitude of
associations and effect sizes of MHC variants are greater in early-
onset cases than late-onset cases20,21. Thus, for all three diseases
the MHC appears to play a special role in mediating age-of-onset.
Early vitiligo onset is speciﬁcally associated with the MHC class
II region indel rs145954018, which contributes substantially to
the heritability difference between the early-onset and late-onset
subgroups. The high-risk deletion allele is uncommon, with MAF
3 to 4% in most human populations [https://www.ncbi.nlm.nih.
gov/projects/SNP/snp_ref.cgi?rs=145954018]. Its frequency is
much lower, with MAF about 0.5%, in east Asians, a population
in which the prevalence of vitiligo is likewise much lower than
in others22–24. In contrast, the MAF of the rs145954018del risk
allele is 15% among early-onset vitiligo cases and is 19% among
cases with disease onset from ages 5–9 years. The rs145954018del
risk allele is in almost complete LD with the most signiﬁcant
MHC class II locus found by our previous GWAS, rs9271597,
which is generically associated with both early- and late-onset
vitiligo. The rs145954018del-rs9271597A haplotype carrying
the risk alleles of both variants confers a remarkable 8-fold
elevation of vitiligo risk and dominantly accelerates vitiligo onset
by about 9 years. Nevertheless, even among early-onset vitiligo
cases only 28% carry the high-risk rs145954018del-rs9271597A
haplotype, indicating that other factors also contribute to early
vitiligo onset.
The high-risk rs145954018del-rs9271597A haplotype resides
on the extended MHC class II haplotype rs145954018del-HLA-
DRB1*13:01-HLA-DRB3*01:01-rs9271597A-HLA-DQA1*01:03-
HLA-DQB1*06:03. The main effects of the extended haplotype on
vitiligo risk and age-of-onset are attributable to rs145954018, and
to a lesser extent rs9271597; the classical HLA alleles in LD on the
extended haplotype do not appear to show additional indepen-
dent effects. Nevertheless, these classical HLA alleles might exert
other effects, and protection by HLA-DRB1*13:01 likely accounts
for the unexpectedly lower frequency of other autoimmune dis-
eases in early-onset vitiligo cases than in late-onset cases.
rs145954018 and rs9271597 are both located within lymphoid-
speciﬁc transcriptional enhancers. The high-risk rs145954018del
allele and the rs145954018del-rs9271597A haplotype are speciﬁ-
cally associated with increased expression of HLA-DQ protein on
peripheral monocytes and dendritic cells. Taken together, our
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ﬁndings are consistent with a model in which the effects
of rs145954018del and rs9271597A are synergistic, the
rs145954018del-rs9271597A haplotype increasing expression of
HLA-DQB1 mRNA thereby increasing expression of HLA-DQ
protein on the surface of professional antigen presenting cells.
Increased surface presentation of triggering antigens by HLA-DQ
molecules may increase the probability of autoreactive T-cell
activation, and thus may both increase overall vitiligo risk and
accelerate vitiligo onset. This process is presumably initiated
by environmental insult, though it is unknown what triggers
might especially pertain to the 5–9 year age group, which appears
to be particularly relevant to vitiligo associated with the
rs145954018del-rs9271597A haplotype.
Extreme vitiligo risk and early disease onset is thus speciﬁcally
associated with a haplotype of MHC class II regulatory variants
that quantitatively affect HLA protein expression. For other
autoimmune diseases, most studies have focused on the role of
coding variations that encode structurally different HLA proteins.
Regulatory variation in the MHC remains largely unexplored,
and may play a generally unrecognized yet signiﬁcant role in
the pathogenesis of many autoimmune diseases.
Methods
Study subjects. GWAS cases were from our three previous vitiligo GWAS1 (1,381
cases)2, GWAS2 (413) cases4, and GWAS3 (1,059 cases)5, and GWAS control data
sets were obtained from the database of Genotypes and Phenotypes (dbGaP).
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Control datasets were phs000092.v1.p1, phs000125.v1.p1, phs000138.v2.p1,
phs000142.v1.p1, phs000168.v1.p1, phs000169.v1.p1, phs000206.v3.p2, phs000237.
v1.p1, phs000346.v1.p1, and phs000439.v1.p1 for GWAS1; phs000203.v1.p1, and
phs000289.v2.p1 for GWAS2; phs000196.v2.p1, phs000303.v1.p1, phs000304.v1.
p1, phs000368.v1.p1, phs000381.v1.p1, phs000387.v1.p1, phs000389.v1.p1,
phs000395.v1.p1 phs000408.v1.p1, phs000421.v1.p1, phs000494.v1.p1, and
phs000524.v1.p1 for GWAS3). Control datasets were matched to each of the three
GWAS case datasets based on platforms used for genotyping. The replication study
included 1,743 cases and 2,182 unaffected controls from our previous independent
replication study5. All subjects were unrelated and of self-described non-Hispanic/
Latino European-derived white ancestry from North America and Europe. All cases
met diagnostic criteria for generalized vitiligo1. We obtained written informed
consent from all study participants, and the study was approved by the institutional
review board at each participating center, with overall oversight provided by the
Colorado Multiple Institutional Review Board (COMIRB).
Age-of-onset analyses. All cases provided self-reported vitiligo age-of-onset. To
deﬁne the mixture of age-of-onset distributions in the GWAS and replication case
cohorts, we performed goodness of ﬁt analyses using the ﬁnite mixture model
(FMM) procedure in SAS version 9.4 [https://www.sas.com]. We set component
distributions as normal, the maximum number of mixture components as seven, ﬁt
the FMMs using the maximum likelihood method, and chose the best ﬁt model
using the Bayesian information criterion (BIC).
Genotyping, quality control and imputation. Genome-wide genotyping, quality
control procedures, and genome-wide imputation were described previously2,4,5. To
increase genetic resolution in the MHC, we used the Sanger Imputation Service
[https://imputation.sanger.ac.uk/] to impute SNP genotypes using the Haplotype
Reference Consortium reference panel (release 1.1) [http://www.haplotype-reference-
consortium.org/]. We used Eagle225 to pre-phase genotypes to produce best-guess
haplotypes and then performed imputation using PBWT26. SNPs with imputation
INFO> 0.5, minor allele frequency ≥ 0.001 from the three GWAS combined, and
without signiﬁcant (P < 1 × 10−5) deviation from Hardy–Weinberg equilibrium were
retained and combined with variants previously genotyped or imputed with
IMPUTE227 from the previous GWAS;5 for SNPs imputed by both IMPUTE2 and
PBWT, the PBWT imputed genotypes were retained. We imputed classical HLA
alleles and amino acid polymorphisms for the three previous GWAS using SNP2HLA
and the Type 1 Diabetes Genetics Consortium reference panel13. In total, 53,976
MHC variants and MHC classical alleles were tested in the ﬁnal analysis.
In the replication study, rs145954018 and rs9271597 were genotyped using the
Applied Biosystems SNaPshot Multiplex System. Both variants had genotype call
rates > 95% and were in Hardy–Weinberg equilibrium (P > 0.05).
Homogenous case-control clusters and eigenvectors. To control for population
stratiﬁcation in the GWAS data, we derived homogenous case-control clusters and
signiﬁcant eigenvectors for each GWAS cohort separately using GemTools12 with
the default parameter settings. For each GWAS cohort, we used genotyped SNPs
with genotype missing rate < 0.1%, MAF > 0.01, and Hardy–Weinberg P value >
0.005, and chose tag SNPs with r2 < 0.01 using PLINK28 version 1.9. The number of
tag SNPs used for GWAS1, GWAS2, and GWAS3 were 13,459, 12,140, and 13,010,
respectively. Signiﬁcant eigenvectors for genetic ancestry were derived from the
normalized graph Laplacian, with the number of signiﬁcant eigenvectors estimated
based on the eigengap heuristic and hypothesis testing29. Homogeneous case-
control clusters were derived by k-means clustering using Ward’s algorithm30,
using a matrix including the signiﬁcant eigenvectors, normalized using the NJW
algorithm31.
Early-onset and late-onset subgroup stratiﬁcation. To stratify cases from each
GWAS into early-onset and late-onset vitiligo subgroups, we included only cases
with > 80% posterior probability of belonging to either the early-onset (GWAS1,
1–10 years; GWAS2 1–13; GWAS3 0–14) or late-onset (GWAS1, 19–84 years;
GWAS2, 22–72; GWAS3, 21–81) case subgroup based on the best ﬁt FMM for each
GWAS. Posterior probabilities were derived from the FMM procedure in SAS
version 9.4. All cases assigned to either the early- or late-onset subgroup were
assigned to genetically homogeneous clusters with controls from the corresponding
cohort using GemTools12. We then combined the three early-onset case-control
subgroups (704 cases and 9,031 controls) and three late-onset case-control sub-
groups (1,467 cases and 19,156 controls).
Cases in the replication cohort were stratiﬁed into early-onset (n= 375, 2–11
years) and late-onset (n= 977, 21–81 years) subgroups as above. To compensate
for sample size differences between the two subgroups, we used simple random
sampling implemented in the SURVEYSELECT procedure in SAS version 9.4 to
randomly assign two-thirds (n= 1455) of controls to the early-onset subgroup
and one-third (n= 727) to the late-onset subgroup.
Association analyses. We performed separate GWAS in the early- and late-onset
subgroups, with no overlap of subjects between the two subgroups. To control for
population stratiﬁcation, we performed Cochran-Mantel-Haenszel (CMH) analysis
using GemTools-derived clusters from each GWAS as strata. For chromosome X
variants, we assumed complete X-inactivation and similar effect sizes in males and
females, with the effect of one risk allele in males equal to the effect of two risk
alleles in females. Excluding variants within the extended MHC, the genomic
inﬂation factors for the early-onset and late-onset subgroups were 1.046 and 1.064,
respectively. For each variant that achieved genome-wide signiﬁcant association
(PCMH < 5.0 × 10−8) in either or both age-of-onset subgroups, we tested whether
the effect size was signiﬁcantly different in the two subgroups using a Z test32,
calculating Z as the difference between the logarithms of the ORs, divided by the
square root of the sum of the variances of the logarithms of the ORs, where Z
follows a normal distribution. Given 6,273 SNPs tested genome-wide, and with
many SNPs in the MHC region in linkage disequilibrium, we considered PZ < 5.0 ×
10−5 as the signiﬁcant effect size difference criterion.
For the replication study, we performed logistic regression analyses of
rs145954018 and rs9271597 in the early- and late-onset subgroups.
For all logistic regression analyses using the GWAS or GWAS plus replication
study data, we included signiﬁcant eigenvectors for each GWAS as covariates to
control for population stratiﬁcation.
To test whether there are other variants representing the same signals as
rs145954018 and rs927159 in the combined GWAS data, we performed logistic
regression analysis for all MHC region variants conditional on rs145954018 or
rs927159. If a tested variant and the conditional variant in the same model could
not improve each other signiﬁcantly (both with Pconditional > 0.05), both were
considered to represent the same signal.
To compare dominant versus additive effect models for the rs145954018del-
rs9271597A haplotype, we ﬁrst ﬁt a logistic regression model with the additive
effect of the haplotype (coded as 0, 1, 2 for having 0, 1, or 2 copies) and an extra
term for dominance effect (coded 1 for possessing exactly 1 copy of the haplotype
and 0 otherwise; Supplementary Table 4). As a signiﬁcant dominance effect was
detected (P= 1.06 × 10−2), we tested complete versus incomplete dominance by
Table 2 Allele-speciﬁc expression of HLA class II genes in whole blood cell mRNA
Subjecta Subject 1 Subject 2 Subject 3
rs145954018-rs9271597 phased haplotypes GT-T | GT-T del-A | GT-T del-A | GT-T
HLA-DRB1-HLA-DQA1-HLA-DQB1 phased haplotypes *01:01-*01:01-*05:01 *13:01-*01:03-*06:03 *13:01-*01:03-*06:03
*08:02-*04:01-*04:02 *03:01-*05:01-*02:01 *12:01-*05:01-*03:09
HLA-DRA RNA Total (RPKM) 54.8 40.0 51.2
HLA-DRB1 RNA Total (RPKM) 66.4 93.5 70.4
Allele 1 *01:01 43% *13:01 43% *13:01 58%
Allele 2 *08:02 57% *03:01 57% *12:01 42%
HLA-DQA1 RNA Total (RPKM) 13.1 11.0 12.3
Allele 1 *01:01 36% *01:03 69% *01:03 79%
Allele 2 *04:01 64% *05:01 31% *05:01 21%
HLA-DQB1 RNA Total (RPKM) 16.5 42.8 34.2
Allele 1 *05:01 55% *06:03 84% *06:03 69%
Allele 2 *0402 45% *02:01 16% *03:09 31%
For HLA-DRB1, HLA-DQA1, and HLA-DQB1 RPKM and the percentage of reads mapping to the most likely HLA classical alleles from seq2HLA software35 are shown, reﬂecting allele-speciﬁc expression.
HLA-DRA is non-polymorphic; therefore, allele-speciﬁc expression cannot be ascertained.
RPKM Reads Per Kilobase of transcript, per Million mapped reads (normalized RNA expression)
aThe data are related to Fig. 5
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comparing the BIC of the model with complete dominance effect (coded as 0, 1, 1
for having 0, 1, or 2 copies of the haplotype) versus the model with both additive
and dominance effects, and the model with complete dominance effect showed
lower BIC, suggesting that a model in which the haplotype is completely dominant
is a better description of the data. We used the combined data for the early-onset
subgroup from the three GWAS and the replication study for the analysis.
To dissect the relative contributions of rs149554018, rs9271597, and the
classical HLA alleles to vitiligo risk in the combined GWAS data, we compared
logistic regression models of haplotypes deﬁned by different combinations of
rs145954018, rs9271597, HLA-DRB1*13:01, HLA-DQA1*01:03, and HLA-
DQB1*06:03, and used BIC to select the best ﬁt model.
To calculate the odds ratio of developing vitiligo at age of 5–9 years for
individuals carrying the rs145954018del-rs9271597A haplotype versus not, we
performed logistic regression analysis using cases with age-of-onset of 5 to 9 and
Gem-tools12 genetic-matched controls from the three GWAS and the replication
study. A total of 464 cases and 10,720 controls were used for the analysis.
We compared frequencies of vitiligo cases with self-reported afﬂiction with
other, concomitant autoimmune diseases including type 1 diabetes, Grave’s
Disease, Hashimoto thyroiditis, Addison disease, systemic lupus erythematosus,
pernicious anemia, and rheumatoid arthritis in early- and late-onset cases using
Fisher’s exact test.
To test association between non-vitiligo autoimmunity and HLA-DRB1*13:01
and rs145954018, we coded vitiligo cases having at least one other vitiligo-associated
autoimmune diseases (autoimmune thyroid disease, type 1 diabetes, pernicious
anemia, rheumatoid arthritis, systemic lupus erythematosus, and Addison disease)
as 1 and 0 otherwise, and used this phenotype as the responsible variable in logistic
regression models, testing the additive effects of HLA-DRB1*13:01 and
rs145954018del both individually and together. 540 vitiligo cases from the combined
GWAS having at least one other vitiligo-associated autoimmune diseases and 1,824
without were used in the analysis. For protein expression, we performed linear
regression analysis to test separately the association between HLA-DQ and HLA-
DR protein expression levels and the allele counts of rs145954018del, rs9271597A,
and haplotype count of rs145954018del-rs9271597A.
Estimation of heritability. To estimate total vitiligo heritability in the separate
early-onset and late-onset subgroups, we performed LD- and MAF-stratiﬁed
GREML (GREML-LDMS)33 analysis using the genome-wide imputed genotype
data of the two subgroups, including the signiﬁcant eigenvectors for each of the
three GWAS as covariates in the analysis. After quality control procedures
(imputation r2 info > 0.6, MAF > 0.01, and Hardy–Weinberg equilibrium P > 1 × 10
−5), a total 8,593,074 variants were retained for the analyses. To estimate the
phenotypic variance explained by the previously identiﬁed non-MHC and MHC
class I vitiligo susceptibility loci, we examined all variants within each non-MHC
locus, deﬁning region boundaries where the PCMH-values gradually increased to
0.05, and we speciﬁed the MHC class I region as previously deﬁned34. We then re-
ran GREML-LDMS using the genome-wide imputed data excluding all variants
within the region boundaries deﬁned for non-MHC loci and the MHC class I
region. The difference between the total phenotypic variance explained before and
after removing variants at the non-MHC loci and MHC class I region was con-
sidered as the phenotypic variance explained by these loci. We calculated pheno-
typic variance explained by rs145954018 and/or rs9271597 as the McFadden’s
pseudo r2 difference between the logistic regression model including the signiﬁcant
eigenvectors for each of the three GWAS plus either or both variants and the model
including only the signiﬁcant eigenvectors for each of the three GWAS.
Analysis of MHC class II protein and mRNA. We selected 46 available unrelated,
healthy subjects (n= 27 male, n= 19 female) of non-Hispanic European ancestry
with no known autoimmune diseases or current infections from the replication
cohort of our previous GWAS5 based on genotypes for rs145954018 and rs9271601
(genotypes: rs145954018: GT/GT, n= 33; del/GT, n= 12; del/del, n= 1;
rs9271597: T/T, n= 13, T/A, n= 20; A/A, n= 13; inferred haplotypes: TG-T |
TGT, n= 13; TG-T | TG-A, n= 12; TG-A | TG-A, n= 8; TG-T | del-A, n= 8; TG-
A | del-A, n= 4; del-A | del-A, n= 1).To assay leukocyte surface HLA-DR and
HLA-DQ proteins, peripheral venous blood was collected and ﬂow cytometry was
performed (Supplementary Fig. 4), using as antibodies PerCP-Cy5.5 anti-CD1c
(BioLegend Cat# 331514, RRID AB_1227535); Brilliant Violet 785 anti-CD3
(BioLegend Cat# 317330; RRID AB_2563507); PE-Cy7 anti-CD11b (BioLegend
Cat# 301322; RRID AB_830644); Brilliant Violet 421 anti-CD11c (BioLegend Cat#
301628; RRID AB_11203895); APC-Cy7 anti-CD14 (BioLegend Cat# 367108;
RRID AB_2566710); Alexa Fluor 488 anti-CD19 (EBioscience Cat# 53-0199-42;
RRID AB_1659677); APC anti-HLA-DR (BioLegend Cat# 307610; RRID
AB_314688); PE anti-HLA-DQ (BioLegend Cat# 318106; RRID AB_604129)
without dilution. Mononuclear cells were selected based on size and granularity
and leukocytes were identiﬁed by CD45 staining. To exclude T and B cells, the CD3
and CD19 double negative population was selected and CD14 and CD11b double
positive cells were used to identify monocytes. Mean ﬂuorescence intensity (MFI)
of HLA-DQ and HLA-DR expression on monocytes (CD3−, CD11b+, CD11c−,
CD14+, CD19−), dendritic cells (CD3−, CD11b−, CD11c+, CD14−, CD19−), B
lymphocytes (CD3−, CD11b−, CD14−, CD19+), and T lymphocytes (CD3+,
CD11b−, CD11c−, CD14−, CD19−) was reported.
For RNA-seq analysis, three healthy subjects were selected from the protein
expression study cohort above; one had phased rs145954018-rs9271597 genotypes
TG-T | TG-T and two had phased genotypes TG-T | del-A. For each subject,
peripheral venous blood was obtained and whole blood RNA-seq was performed.
For allele-speciﬁc expression analysis, we ﬁrst used seq2HLA35 to perform
HLA-typing using RNA-seq from each of the three subjects. We then aligned
RNA-seq reads only to reference sequences for that subject’s speciﬁc HLA type.
The number of reads aligning to the most-likely HLA-DRB1, HLA-DQA1, and
HLA-DQB1 alleles in each subject were counted and presented as a ratio, reﬂecting
the relative expression of each allele. Quantiﬁcation of total HLA-DRB1, HLA-
DQA1, and HLA-DQB1 (RPKM) was provided by the standard output of seq2HLA.
Reporting Summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Case genotype and phenotype data for GWAS1, GWAS2, and GWAS3 subjects,
and RNA-seq data for the present study, have been deposited in the Database of
Genotypes and Phenotypes (dbGaP) under accession numbers phs000224.v1.p1,
phs000224.v2.p1, phs000224.v3.p2, and phs000224.v4.p2). Vitiligo susceptibility
and age-of-onset GWAS summary statistics have been deposited in the NHGRI-
EBI Catalog of published genome-wide association studies. The source data
underlying Figs 1, 2a and b, 3, 5a and b, and Supplementary Figs 1a and b, 2a-l, and
3a-d are provided as a Source Data ﬁle.
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